MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Substantia nigra"

  • 2016 International Congress

    Substantia nigra hyperechogenicity in Mexican patients with Parkinson’s disease

    C.Y. Rodriguez-Garza, A. Anaya-Escamilla, R. Pinales-Razo, I. Estrada-Bellmann, C.R. Camara-Lemarroy (Monterrey, Mexico)

    Objective: To determine the prevalence of increased echogenicity in the substantia nigra in patients diagnosed with idiopathic Parkinson's disease at the University Hospital "Dr. José…
  • 2016 International Congress

    SOD1 aggregation: A pathological link between Parkinson’s disease and amyotrophic lateral sclerosis?

    B.G. Trist, K.M. Davies, S. Genoud, V. Smoothy, G.M. Halliday, S. Roudeau, A. Carmona, L. Perrin-Verdugier, R. Ortega, K.L. Double (Sydney, Australia)

    Objective: To characterize (1) a novel association between superoxide dismutase 1 (SOD1) aggregation and neuronal loss in the Parkinson's disease (PD) brain and (2) the…
  • 2016 International Congress

    AMP kinase regulates ligand-gated K-ATP channels in substantia nigra dopamine neurons

    S.W. Johnson, Y. Wu, A.C. Munhall, K.Z. Shen (Portland, OR, USA)

    Objective: To characterize the effect of AMP-activated protein kinase (AMPK) on ATP-sensitive K+ (K-ATP) channels on substantia nigra compacta (SNC) dopamine neurons in slices of…
  • 2016 International Congress

    Astroglia exert a neuro-protective role in Parkinson’s disease by reducing oxygen stress through dopamine-induced activation of the pentose-phosphate pathway

    K. Mashima, S. Takahashi, T. Iizumi, T. Abe, N. Suzuki (Tokyo, Japan)

    Objective: Although dopaminergic neurons themselves take up most of the released dopamine (DA), a part of the DA appears to be taken up by astroglia.…
  • 2016 International Congress

    Engrailed enhances dopamine synthesis in healthy dopaminergic neurons

    D. Alvarez-Fischer, M. Baaske, F. Vulinovic, J. Fuchs, P. Seibler, A. Rakovic, A. Prochiantz, C. Klein (Lübeck, Germany)

    Objective: The aim of the present study was to further elucidate the role of Engrailed in dopamine neurotransmission. Background: Engrailed1 and Engrailed2, collectively Engrailed, are…
  • 2016 International Congress

    Glatiramir acetate (Copaxone) causes restoration of the striatal dopamine in a progressive MPTP mouse model of Parkinson’s disease

    C.K. Meshul, M.J. Churchill (Portland, OR, USA)

    Objective: To assess if a microglial modulator, Glatiramer Acetate (GA), can restore loss of striatal dopamine (DA) and behavioral deficits following progressive 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP)…
  • 2016 International Congress

    Exploring therapeutic viability of a non-dopaminergic target for Parkinson’s disease

    A. Ashrafi, M. Buttini, P. Garcia, A. del Sol, E. Glaab (Esch-sur-Alzette, Luxembourg)

    Objective: Non-dopaminergic protein drug targets are of high interest to develop adjuvant treatments for currently insufficiently addressed symptoms of PD. RGS4, a regulator of G-protein…
  • 2016 International Congress

    Vagus nerve stimulation as a novel treatment strategy for Parkinson’s disease

    A. Farrand, R. Gregory, K. Helke, S. Hays, V. Hinson, H. Boger (Charleston, SC, USA)

    Objective: To assess the therapeutic potential of chronic vagus nerve stimulation (VNS) to attenuate the behavioral and neuronal deficits observed in Parkinson's disease (PD) by…
  • 2016 International Congress

    Diffusion tensor imaging biomarkers of nigrostriatal neurodegeneration in early Parkinson’s disease

    J.A. Pineda-Pardo, G. Foffani, J.A. Obeso (Madrid, Spain)

    Objective: Identify magnetic resonance imaging (MRI) biomarkers of nigrostriatal neurodegeneration in early-stage drug-naïve Parkinson's disease (PD). Background: Diffusion tensor imaging (DTI) is an MRI technique…
  • 2016 International Congress

    The study of clinical outcome of deep brain stimulation for the idiopathic Parkinson’s disease at 6 months follow-up

    P. Papitak, M. Aphiwatthanakun, T. Srikijvilaikul, N. Limotai (Bangkok, Thailand)

    Objective: The aim of this study was to assess the motor and psychiatric outcomes at 6 months after subthalamic nucleus deep brain stimulation (STN-DBS) in…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • #28953 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley